18F-PI2620 Tau-PET in Progressive Supranuclear Palsy - A multi-center evaluation

Conclusions: The results of this preliminary multi-center evaluation indicate a value of 18F-PI2620 to diagnose and differentiate suspected PSP patients in vivo. The magnitude of tracer binding between patients seems to be variably expressed but not correlated with disease severity. These results indicate that 18F-PI2620 may show potential as a biomarker to assess tau pathology in PSP patients and that it may be helpful to establish earlier and more reliable diagnosis of PSP.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Brendel, M., Barthel, H., Van Eimeren, T., Marek, K., Beyer, L., Song, M., Palleis, C., Hammes, J., Saur, D., Schroeter, M., Rumpf, J.-J., Rullmann, M., Schildan, A., Patt, M., Madonia, J., Russell, D., Stephens, A., Roeber, S., Levin, J., Classen, J., Ho Tags: Brain Imaging Council YIA Symposium Source Type: research